Sentences with phrase «of medical device companies»

The list of medical device companies offering jobs in medical device includes companies such as Medtronic, Stryker, Bard, Karl Storz, and St Jude Medical and many others.

Josh has over thirty years of in - depth experience in research, development, manufacturing, regulatory affairs and general management of medical device companies.

I approached a number of medical device companies and found out it was a lot easier to sell a product than to sell an idea.

William Blair Investment Management LLC now owns 1,762,619 shares of the medical device company's stock worth $ 101,157,000 after purchasing an additional 344,294 shares in the last quarter.

AXA now owns 1,911,206 shares of the medical device company's stock worth $ 109,684,000 after purchasing an additional 592,275 shares in the last quarter.

OppenheimerFunds Inc. now owns 1,495,535 shares of the medical device company's stock worth $ 85,829,000 after purchasing an additional 734,325 shares in the last quarter.

Mackenzie Financial Corp now owns 1,371,595 shares of the medical device company's stock worth $ 78,716,000 after purchasing an additional 87,848 shares in the last quarter.

In my industry (I am the VP of a medical device company), Physicians have to disclose conflicts of interest as well as financial relationships with industry when they publish papers.

ONC Solutions, Location 2007 — Present Founder, Co-Owner, and Sales Manager Spearheaded operations and instrumental as an integral part in the start - up of medical device company specializing in fiducial markers for radiation oncology.

Meyers previously served as COO of medical device company Biolyst, LLC, d / b / a Realief Neuropathy Centers, and in client engagement and client service leadership roles at SIRVA Relocation.

Not exact matches

But the trade - off of this focus on shareholder value is spending that benefits other stakeholders, like employees and customers, said Bill George, the former CEO of medical - device company Medtronic.

Vivek Kopparthi is the co-founder and CEO of NeoLight, an empathy - driven technology company primarily focused on lean medical devices for newborn care.

With Fitbit, Park is partnering with a host of companies and his gadget company is increasingly embedded in the traditional health care sector as it works with insurers, medical device companies, and employers to try to figure out how to motivate and engage individuals in behaviors that can help manage chronic conditions as well as general wellness.

• Nexcore Technology, a portfolio company of Kidd & Company, acquired Phase 2 Medical Manufacturing, a manufacturer of medical devices with locations in Rochester, N.H., Lafayette, Colo., and Tijuana, company of Kidd & Company, acquired Phase 2 Medical Manufacturing, a manufacturer of medical devices with locations in Rochester, N.H., Lafayette, Colo., and Tijuana, Company, acquired Phase 2 Medical Manufacturing, a manufacturer of medical devices with locations in Rochester, N.H., Lafayette, Colo., and Tijuana, Medical Manufacturing, a manufacturer of medical devices with locations in Rochester, N.H., Lafayette, Colo., and Tijuana, medical devices with locations in Rochester, N.H., Lafayette, Colo., and Tijuana, Mexico.

• INSIGHTEC, an Israeli medical device company specializing in non-invasive treatment of brain conditions using MR - guided focused ultrasound, raised $ 150 million in Series E funding.

Different types of business require more capital than others (e.g., a medical device company would require more capital than a hair salon).

The developer of a gun safety device has become the fifth Israeli company in the technology or medical cannabis sectors to pursue a listing on the ASX through either an IPO or a reverse takeover of a moribund WA mining company.

Regenerative medicine company Avita Medical has raised $ 10 million from investors to support the commercialisation of its ReCell device, which is being trialled by a US government agency.

«IBM and the FDA will explore the exchange of owner mediated data from several sources, such as Electronic Medical Records, clinical trials, genomic data, and health data from mobile devices, wearables and the «Internet of Things,»» said the company in a press release.

The company is selling a thing (the kit) by saying it can provide «health reports on 254 diseases and conditions,» including categories such as «carrier status,» «health risks,» and «drug response,» and specifically as a «first step in prevention» that enables users to «take steps toward mitigating serious diseases» such as diabetes, coronary heart disease, and breast cancer...» Most of the uses «listed on your website, a list that has grown over time,» the FDA writes, «are medical device uses [for the] Personal Genome Service.»

While he was CEO of Medtronic, a medical device and technology company, from 1991 to 2001, the company's market cap grew from $ 1 billion to $ 60 billion.

But Carbon3D's technology creates 3D objects «like a chemist grows crystals,» said DeSimone, who previously co-founded a number of companies including medical device makers.

Investors can participate in the potential of companies such as TIO Networks Corp. (TSXV: TNC), an expedited bill - payment processor, which recorded $ 36.5 million in revenues in 2011, an increase of almost 50 % over the previous year, and Verisante Technology Inc. (TSXV: VRS), a medical device company that commercializes cancer detection systems using a platform developed by the BC Cancer Agency.

Chris has worked with many of the world's leading companies in medical devices, building products, chemicals, pharmaceuticals, agribusiness and other industries.

The prototype, which Google says will take at least five years to reach consumers, is one of several medical devices being designed by companies to make glucose monitoring for diabetic patients more convenient and less invasive than the traditional finger pricks.

«We've responded to the competitive environment by focusing on industries that are currently out of favor with the public - equity market, like biotech, medical devices, and early - stage information - technology companies,» says Patrick Boroian, a general partner at Sprout, which is the New York City - based venture - capital affiliate of financial - services giant Donaldson, Lufkin & Jenrette.

«There are hundreds of pharmaceutical companies of significant scale and dozens of significantly scaled medical device companies to combine around therapeutic areas.»

In Europe, new rules affecting medical device manufacturers, particularly the Medical Device Regulation, will force companies to examine their portfolios and evaluate the significant costs of meeting these requirmedical device manufacturers, particularly the Medical Device Regulation, will force companies to examine their portfolios and evaluate the significant costs of meeting these requiredevice manufacturers, particularly the Medical Device Regulation, will force companies to examine their portfolios and evaluate the significant costs of meeting these requirMedical Device Regulation, will force companies to examine their portfolios and evaluate the significant costs of meeting these requireDevice Regulation, will force companies to examine their portfolios and evaluate the significant costs of meeting these requirements.

Most recently, Mr. Nawana served as CEO of medical diagnostics company Alere Inc., prior to Alere, he spent 15 years at Johnson & Johnson primarily in its Medical Device & diagnostics smedical diagnostics company Alere Inc., prior to Alere, he spent 15 years at Johnson & Johnson primarily in its Medical Device & diagnostics sMedical Device & diagnostics segment.

The Fisher - Barton Group of independent companies leverage their materials expertise and world leading process innovations to manufacture high value components for a variety of markets including agricultural equipment, converting equipment, outdoor power equipment, medical device, recycling equipment and solar power.

Hosted by Johnson & Johnson, supported by Heidrick & Struggles Marne Levine, Chief Operating Officer, Instagram Interviewer: Mellody Hobson, President, Ariel Investments Remarks: Nefertiti Greene, Vice President, Global Platform Leader, Wound Closure and Repair, Ethicon, Inc. — A Johnson and Johnson Medical Device Company Remarks: Anne Lim O'Brien, Vice Chairman, CEO and Board of Directors Practice, Heidrick & Struggles

Introduction and Celebration of the MPW High School Mentees Emcee: Michal Lev - Ram, Fortune Remarks: Nefertiti Greene, Vice President, Global Platform Leader, Wound Closure and Repair, Ethicon, Inc. — A Johnson and Johnson Medical Device Company Bonnie Gwin, Vice Chairman & Managing Partner, Board of Directors Practice, Heidrick & Struggles

The company is leader across a wide variety of healthcare business segments, including medical devices, pharmaceuticals and over-the-counter medications.

Erin's primary responsibilities at RA Capital are to manage the design and creation of all internal and external documents and resources for the company, including competitive landscapes of drugs and medical devices for disease indications and capabilities, set brand standards, and oversee internal and external marketing efforts.

We partner with and have unparalleled access to leading innovative healthcare providers, payers, medical device companies, laboratory services provider, healthcare retailer, and one of the largest owners of healthcare campuses.

Rob Tyler has dedicated the past 17 years to helping entrepreneurs grow emerging technology companies in a variety of industries, including information technology, life sciences, medical devices, healthcare, nanotechnology, and advanced materials.

She joined Wellcap Partners as an assistant portfolio manager, followed by a role at Boston Avenue Capital as a portfolio manager, during which time she took a role as interim Chief Operations Officer of Compumed, a public company specializing in medical devices for osteoporosis testing.

Dr. Hopfield is a former Partner of McKinsey & Company in its global pharmaceuticals and medical devices practice, where she led work in strategy, R&D management, and marketing across pharmaceutical, biotech, medical device and consumer industries.

Represented medical device and biotechnology companies in initial incorporation and multiple rounds of Preferred Stock financing.

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.

The company develops and markets a broad range of medical devices, such as advanced surgical technology, insulin pumps, transcatheter aortic heart valves, and much more.

J&J generates billions of dollars in annual sales from selling consumer goods, such as Band - Aid products, and medical devices used in surgeries, but it's the company's pharmaceuticals business that determines whether the company's results are better or worse than anticipated.

With several drugs currently acting as significant drivers of growth, J&J's pharmaceutical segment looks well placed even as the company strives to maintain its market share in consumer healthcare and medical devices.

This is a medical devices and technology company that develops, manufactures, and markets a variety of therapeutic products to hospitals, physicians, clinicians, and patients across approximately 160 countries.

A serial entrepreneur of medical device and life sciences companies, he advises life science inventors and entrepreneurs on strategy and is active in company formation and financing.

This was followed by many global Learning Management and gamified solutions for some of the top medical device, pharmaceutical and biotech companies in the world.

Though this simple medical device contains only about $ 1 of the drug epinephrine, the company that sells it, Mylan, earned the public's enmity and lawmakers» scrutiny after ratcheting up prices to $ 609 a box.

Shares of the heart recovery medical device maker jumped as much as 12 % in early morning trading on Thursday after the company reported stellar fiscal 2018 fourth - quarter results and issued bullish guidance.

HOOPP was an initial private equity investor at Teranet's founding, remained the largest shareholder when the company was taken public on the TSX, and eventually sold its stake into a $ 2.0 billion take - over bid in 2008; Ducati Motorcycle Company, initially an NYSE / Milan listed Italian sport motorcycle manufacturer, which was the subject of a deleveraging capital increase, taken private and eventually sold to Volkswagen / Audi Group in 2012 for US$ 1.1 billion; and Novadaq Technologies Inc., a medical devices company in which HOOPP was the largest private investor, with such company completing an initial public offering on the TSX in 2005 and which continues today with a market capitalization in excess of $ 730 mcompany was taken public on the TSX, and eventually sold its stake into a $ 2.0 billion take - over bid in 2008; Ducati Motorcycle Company, initially an NYSE / Milan listed Italian sport motorcycle manufacturer, which was the subject of a deleveraging capital increase, taken private and eventually sold to Volkswagen / Audi Group in 2012 for US$ 1.1 billion; and Novadaq Technologies Inc., a medical devices company in which HOOPP was the largest private investor, with such company completing an initial public offering on the TSX in 2005 and which continues today with a market capitalization in excess of $ 730 mCompany, initially an NYSE / Milan listed Italian sport motorcycle manufacturer, which was the subject of a deleveraging capital increase, taken private and eventually sold to Volkswagen / Audi Group in 2012 for US$ 1.1 billion; and Novadaq Technologies Inc., a medical devices company in which HOOPP was the largest private investor, with such company completing an initial public offering on the TSX in 2005 and which continues today with a market capitalization in excess of $ 730 mcompany in which HOOPP was the largest private investor, with such company completing an initial public offering on the TSX in 2005 and which continues today with a market capitalization in excess of $ 730 mcompany completing an initial public offering on the TSX in 2005 and which continues today with a market capitalization in excess of $ 730 million.

The six - part deal came ahead of Abbott's split into two companies, a pharmaceuticals business and a medical - devices manufacturer, which will retain the Abbott Laboratories name.